Pathologisches Institut
Refine
Has Fulltext
- yes (334)
Is part of the Bibliography
- yes (334)
Year of publication
Document Type
- Journal article (200)
- Doctoral Thesis (133)
- Review (1)
Keywords
- NFATc1 (17)
- apoptosis (15)
- NFAT (10)
- immunohistochemistry (10)
- lymphoma (10)
- Transkriptionsfaktor (9)
- Apoptose (8)
- B-Zell-Lymphom (8)
- CXCR4 (8)
- DLBCL (8)
- Non-Hodgkin-Lymphom (8)
- cancer (8)
- T-Lymphozyt (7)
- prognosis (7)
- Apoptosis (6)
- Lymphom (6)
- T cells (6)
- breast cancer (6)
- gene expression (6)
- glioblastoma (6)
- multiple myeloma (6)
- thymoma (6)
- thymus (6)
- B cells (5)
- Lymphome (5)
- Proliferation (5)
- astrocytoma (5)
- follicular lymphoma (5)
- glioblastoma multiforme (5)
- recurrence (5)
- therapy (5)
- Amplifikation (4)
- Autoaggressionskrankheit (4)
- EGFR (4)
- FISH (4)
- Fluoreszenz-in-situ-Hybridisierung (4)
- Follikuläres Lymphom (4)
- Immunhistochemie (4)
- Immuntherapie (4)
- Krebs <Medizin> (4)
- Microarray (4)
- NF-AT (4)
- Prognose (4)
- Thymom (4)
- Thymus (4)
- amplification (4)
- brain (4)
- chemokine receptor (4)
- expression (4)
- forensic neuropathology (4)
- gene regulation (4)
- mRNA (4)
- machine learning (4)
- metastasis (4)
- relapse (4)
- thymic carcinoma (4)
- transcription factors (4)
- B-Lymphozyten (3)
- Brustkrebs (3)
- CGH (3)
- EBV (3)
- Ependymom (3)
- Genexpression (3)
- Histopathologie (3)
- Hodgkin lymphoma (3)
- Immunglobulin M (3)
- Keimzentrum (3)
- Lymphknoten (3)
- Lymphoma (3)
- Lymphozyten (3)
- MALT1 (3)
- MYC (3)
- Malignes Lymphom (3)
- Medizin (3)
- Multiple Myeloma (3)
- Myasthenia gravis (3)
- NRF2 (3)
- PET/CT (3)
- Pathologie (3)
- Plasmozytom (3)
- T-cell lymphoma (3)
- adrenocortical carcinoma (3)
- biomarker (3)
- brain tumor (3)
- cerebrospinal fluid (3)
- comparative genomic hybridization (3)
- diffuse large B-cell lymphoma (3)
- flow cytometry (3)
- forensic neurotraumatology (3)
- germinal center (3)
- glioma (3)
- loss of heterozygosity (3)
- melanoma (3)
- monoclonal antibody (3)
- myasthenia gravis (3)
- neuronal differentiation (3)
- poor prognosis (3)
- positron emission tomography (3)
- protein (3)
- surgical oncology (3)
- vestibular schwannoma (3)
- AICD (2)
- ATF4 (2)
- Angeborene Immunität (2)
- Antigen (2)
- Antikörper (2)
- B-cell lymphoma (2)
- BCL6 (2)
- CD30 (2)
- CRISPR/Cas9 (2)
- CXCR2 (2)
- Colonkrebs (2)
- Cushing’s syndrome (2)
- Deletion (2)
- Differenzierung (2)
- E-cadherin (2)
- EMT (2)
- Epidermaler Wachstumsfaktor-Rezeptor (2)
- Epstein-Barr-Virus (2)
- Expression (2)
- FFPE (2)
- FGFR (2)
- Glioblastoma (2)
- Graft-versus-leukemia (2)
- HNSCC (2)
- Hodgkin (2)
- Humorale Immunität (2)
- Immuncytochemie (2)
- Immunglobuline (2)
- Immunologie (2)
- Immunotherapy (2)
- Immunsystem (2)
- KEAP1 (2)
- Krebs (2)
- LOH (2)
- Lymphogranulomatose (2)
- MALT (2)
- MALT-Lymphom (2)
- MALT-lymphoma (2)
- MPS1 (2)
- Magenkarzinom (2)
- Magenkrebs (2)
- Mammakarzinom (2)
- Mantelzell-Lymphom (2)
- Mantle cell lymphoma (2)
- Maus (2)
- Methylation (2)
- Methylierung (2)
- Mikrosatellitenanalyse (2)
- Mikrosatelliteninstabilität (2)
- Molekularbiologie (2)
- Monoklonaler Antikörper (2)
- Multiples Myelom (2)
- NAFLD (2)
- NASH (2)
- NHL (2)
- NSCLC (2)
- Nekrose (2)
- Neuroinflammation (2)
- Nfatc1 (2)
- Onkogen (2)
- PD-L1 (2)
- PET (2)
- PTCL (2)
- Plattenepithelcarcinom (2)
- Protein p53 (2)
- Rhabdomyosarcoma (2)
- SC-1 (2)
- Signaltransduktion (2)
- Speicheldrüse (2)
- T-Lymphozyten (2)
- T-Zell-Lymphome (2)
- T-Zellen (2)
- T-cell differentiation (2)
- TAF15 (2)
- TTK (2)
- Thymuskarzinome (2)
- Transkriptionsfaktoren (2)
- Tumor (2)
- Tumorimmunologie (2)
- Tumorsuppressorgen (2)
- USP28 (2)
- VEGF (2)
- alloreactive T cells (2)
- amplicon sequencing (2)
- angiogenesis (2)
- animal model (2)
- antigen (2)
- autoimmune disease (2)
- cancer genomics (2)
- cancer stem cells (2)
- cancer therapy (2)
- cancers and neoplasms (2)
- carcinomas (2)
- case report (2)
- cell staining (2)
- cell-cycle arrest (2)
- chemokine (2)
- chromosomal aberration (2)
- classification (2)
- cytotoxic T cells (2)
- development (2)
- discriminant analysis (2)
- endothelial cells (2)
- enzyme-linked immunoassays (2)
- ependymoma (2)
- extranodal (2)
- gastric carcinoma (2)
- gene (2)
- genetic aberrations (2)
- genetics (2)
- genetische Aberrationen (2)
- grade 3B (2)
- humoral immunity (2)
- imaging (2)
- immune response (2)
- immunohistochemistry techniques (2)
- immunotherapy (2)
- in vivo imaging (2)
- inflammation (2)
- innate immunity (2)
- keratinocytes (2)
- kidneys (2)
- low-grade glioma (2)
- lung cancer (2)
- lymphocytes (2)
- mRNA expression (2)
- malignant tumors (2)
- mantle cell lymphoma (2)
- messenger RNA (2)
- miRNA (2)
- mice (2)
- microenvironment (2)
- microsatellite instability (2)
- mitochondrial DNA (2)
- molecular diagnostics (2)
- molecular imaging (2)
- mouse models (2)
- mutation (2)
- mutations (2)
- natural immunity (2)
- natürliche Antikörper (2)
- natürliche Immunität (2)
- neuroinflammation (2)
- obesity (2)
- organoids (2)
- oxidative stress (2)
- p53 (2)
- pancreatic cancer (2)
- pathogenesis (2)
- plasma cells (2)
- positron emission tomography/computed tomography (2)
- postnatal development (2)
- principal component analysis (2)
- proteomics (2)
- radiotherapy (2)
- rat (2)
- receptor tyrosine kinases (2)
- regression analysis (2)
- regulatory T cells (2)
- senile lymphoproliferation (2)
- signal transduction (2)
- survival (2)
- targeted therapy (2)
- temozolomide (2)
- transcription (2)
- translocation (2)
- tumor immunology (2)
- tumor microenvironment (2)
- tumor suppressor gene (2)
- vitamin D (2)
- - (1)
- 16S-rRNA (1)
- 3D ex vivo models (1)
- 3D lung tumor tissue models (1)
- <sup>18</sup>F-FDG (1)
- <sup>68</sup>Ga-Pentixafor (1)
- AD-AID (1)
- ADAM9 (1)
- ADP-ribosylation toxins (1)
- AICDA (1)
- AID-ΔE4a (1)
- AIDS (1)
- AIRE (1)
- AKT-signaling (1)
- ALCL (1)
- ALK-1 (1)
- AMACR (1)
- AOM/DSS (1)
- APECED (1)
- ATF5 (1)
- ATG7 (1)
- ATM (1)
- Aberrationen (1)
- Activation (1)
- Activation induced cell death/AICD (1)
- Adamantiades-Behçet disease (1)
- Adult (1)
- Akute Ösophagusnekrose (1)
- Allogenic hematopoietic stem cell transplantation (1)
- Alpha therapy (1)
- Alter (1)
- Alzheimerkrankheit (1)
- Amplicon Sequencing (1)
- Anergy (1)
- Aneuploidie (1)
- Antibodies (1)
- Antigen CD30 (1)
- Antigen CD8 (1)
- Antiparanodal Autoantibodies (1)
- Aphthae (1)
- Apoptose-Resistenz (1)
- Apoptoseinduktion (1)
- Appendizitis (1)
- Autoantikörper (1)
- Autoimmune diseases (1)
- Autoimmunerkrankung (1)
- Autoimmungastritis (1)
- Autoimmunkrankheit (1)
- Autoimmunregulator (1)
- Autoregulation (1)
- B Lymphocytes (1)
- B cell lymphoma (1)
- B cell malignancies (1)
- B cell receptor (BCR) (1)
- B lymphocytes (1)
- B-Lymphozyt (1)
- B-Lymphozyt-Tumor (1)
- B-MYB (1)
- B-Zell Lymphome (1)
- B-Zell-Leukämie (1)
- B-Zell-Rezeptor (1)
- B-Zellen Differenzierung (1)
- B-cell Lymphome (1)
- B-cell differentiation (1)
- B-cells (1)
- B-lymphocytes (1)
- BAC-Konstrukt (1)
- BAC-construct (1)
- BARB-4 (1)
- BCL1 rearrangement (1)
- BCL1-Rearrangement (1)
- BCL2 (1)
- BIRC7 (1)
- BLIMP1 (1)
- BRMS1 (1)
- Barrett-Ösophagus (1)
- Bauchfellentzündung (1)
- Bauchspeicheldrüsenkrebs (1)
- Bcl-2-Gen (1)
- Bcl-2-gene (1)
- Behçet’s disease (1)
- Bevacizumab (1)
- Bioluminescence imaging (1)
- Biomarker (1)
- Bisphosphonate (1)
- Blasenkrebs (1)
- Blimp-1 (1)
- Blimp1 (1)
- Blinddarmentzündung (1)
- Bone chips (1)
- Bone marrow cells (1)
- Bone marrow transplantantation (1)
- Bone marrow transplantation (1)
- Braak (1)
- Breast-cancer (1)
- Bruton Tyrosine Kinase (1)
- Burkitt (1)
- Burkitt lymphoma (1)
- Burkitt lymphoma (BL) (1)
- B‐cell lymphoma (1)
- C-Myc (1)
- C/EBP (1)
- C/EBP-Beta (1)
- C/EBPβ (1)
- C3 (1)
- CABG-operation (1)
- CBP (1)
- CCR7 (1)
- CD 27 (1)
- CD-Marker (1)
- CD/metabolism (1)
- CD117 (1)
- CD133 (1)
- CD27 (1)
- CD274 (1)
- CD30-Rezeptor (1)
- CD319 (1)
- CD4+ (1)
- CD40 ligand (1)
- CD5-positive B-Lymphozyten (1)
- CD56 (1)
- CD8 (1)
- CD9 (1)
- CFR-1 (1)
- CHAC1 (1)
- CIITA (1)
- CK5 (1)
- COVID-19 (1)
- CRC (1)
- CRISPR-Cas9 (1)
- CRISPR/Cas-Methode (1)
- CS1 (1)
- CSF (1)
- CTL function (1)
- CTNNB1 (1)
- CX5461 (1)
- CXCL5 (1)
- CXCL8 (1)
- CXCR1 (1)
- CXCR4/SDF-1 (1)
- CXCR5 (1)
- CXCR7 (1)
- CYP24A1 (1)
- CYP2W1 (1)
- Calcineurin (1)
- Calcium (1)
- Cancer (1)
- Cancer genetics (1)
- Cancer treatment (1)
- Cancer/Testis Antigene (1)
- Cancer/Testis antigen (1)
- Candida (1)
- Carcinogenese (1)
- Cartilage Oligomeric Matrix Protein (1)
- Caspase 12 (1)
- Ccl2 (1)
- Chains (1)
- Checkpoint-Inhibitor (1)
- Chemokin (1)
- Chemokin CXCL10 (1)
- Chemokine (1)
- Chemokinrezeptor (1)
- Chemotherapy (1)
- Childhood (1)
- Chromosom 9 (1)
- Chromosome 18 (1)
- Chromosomenaberration (1)
- Cisplatin (1)
- Clonality (1)
- Clonality analysis (1)
- Cocktail (1)
- Cushings syndrome (1)
- Cushing’s disease (1)
- Cytogenetik (1)
- Cytotoxizität (1)
- DCIS (1)
- DCR1 (1)
- DEL(5Q) (1)
- DHAP (1)
- DLBCL multilobated (1)
- DLBCL multilobuliert (1)
- DLBL (1)
- DNA hypermethylation (1)
- DNA methylation (1)
- DNA-PK (1)
- DNS-Reparatur (1)
- DOTATOC (1)
- DT40 cells (1)
- DWI (1)
- Defined burkitts lymphoma (1)
- Delta Repertoire (1)
- Dendritic cells (1)
- Dendritische Zelle (1)
- Design (1)
- Diabetes mellitus (1)
- Diagnostik (1)
- Dickdarmkrebs (1)
- Differentielle Genexpression (1)
- Diffuse großzellige B-Zell Lymphome (1)
- Diffuses großzelliges B-Zell Lymphom (1)
- Diphosphonate (1)
- Durchflusszytometrie (1)
- E-Learning (1)
- EAHP/SH bone marrow workshop (1)
- EATCL (1)
- EBER in situ hybridization (1)
- EBF1 (1)
- EGF (1)
- EL-4 (1)
- EL-4 Zellen (1)
- ERM proteins (1)
- ETL (1)
- EZH1 (1)
- EZH2 (1)
- Endothel (1)
- Enteropathie-Typ (1)
- Entzündung (1)
- Enzephalitis (1)
- Epidemiological study (1)
- Epigenese (1)
- Epigenetics (1)
- Epigenetik (1)
- Epitope (1)
- Epstein-Ba (1)
- Epstein-Barr virus (1)
- Ewing-Sarkom (1)
- Extrafollikuläre Aktivierung (1)
- Extraocular eye muscles (1)
- F-19 MRI (1)
- FADD (1)
- FARS1 (1)
- FDG PET/CT (1)
- FGF-pathway (1)
- FINCA (1)
- FL (1)
- FL3B (1)
- FLT-PET (1)
- FTIR spectroscopy (1)
- Factor receptor (1)
- Fas (1)
- Fibrin glue (1)
- Fluoreszenzaktivierter Zellsortierer (1)
- Forskolin (1)
- Frequency (1)
- Frühdiagnostik (1)
- Frühphase (1)
- Funktionelle Untersuchung (1)
- GABP (1)
- GATA-3 (1)
- GFAP (1)
- GIST (1)
- GLP-1 (1)
- GRP78 (1)
- GSH (1)
- Gallium (1)
- Gen-Anordnung (1)
- Genamplifikation (1)
- Gene (1)
- Gene-expression (1)
- Genetik (1)
- Genitoanal region (1)
- Genome wide analysis (1)
- Genregulation (1)
- Gewebemicroarray (1)
- Gewebeverlust (1)
- Glioma stem cells (1)
- Glykosylierung (1)
- Grad 3B (1)
- Grading (1)
- Graft-versus-host-disease (1)
- GvHD (1)
- GvL (1)
- Gvhd (1)
- H. pylori Gastritis (1)
- H.pylori gastritis (1)
- H2O2 (1)
- H3K27me3 (1)
- HD (1)
- HER2 conversion (1)
- HER2 targeted therapy (1)
- HER2-low (1)
- HHV8 (1)
- HNSC (1)
- HPK1 (1)
- HSC (1)
- Hals-Nasen-Ohren-Heilkunde (1)
- Hals-Nasen-Ohren-Tumor (1)
- Hans algorithm (1)
- Harnblasenkarzinom (1)
- Hautlymphom (1)
- Head (1)
- Head and neck cancers (1)
- Heavy chain mutations (1)
- Helicobacter (1)
- Helicobacter pylori (1)
- Helicobacter-pylori-Infektion (1)
- High-resolution (1)
- Hirntumor (1)
- Histologie (1)
- Histone deacetylase inhibition (1)
- Histopathology (1)
- Hitzeschockprotein (1)
- Hodgkin-Lymphom (1)
- Hodgkin´s disease (1)
- Hsp90 (1)
- Human antibodies (1)
- Humane Antikörper (1)
- Hybridom (1)
- Hypercortisolism (1)
- Hypermutation (1)
- Hypopharynxkarzinom (1)
- IDH (1)
- IDH1/2 (1)
- IFN (1)
- IFN-γ (1)
- IGF1 (1)
- IGF1R (1)
- IGF1R Mutationen (1)
- IGF2BP3 (1)
- IL-10 (1)
- IL-17 (1)
- IL-2 (1)
- IL-4 (1)
- IL-5 (1)
- IL2 (1)
- IMP3 (1)
- IR (1)
- IRF4 (1)
- Ibrutinib (1)
- IgG4 (1)
- IgM (1)
- IgM isotyp (1)
- Images (1)
- Immun-Checkpoint (1)
- Immunbiologie (1)
- Immunfluoreszenz (1)
- Immunhistologie (1)
- Immunisierung (1)
- Immunität <Medizin> (1)
- Immunmodulation (1)
- Immunology (1)
- Immunoreceptors (1)
- Immunosuppression (1)
- Immunphänotyp (1)
- Immunreaktion (1)
- Immunrezeptoren (1)
- In-vivo (1)
- Inflammation (1)
- Insulin like-growth factor Rezeptor (1)
- Insulin-like Growth Factor (1)
- Insulin-like Growth Factor I (1)
- Intestinal Intraepithelial Lymphocy (1)
- Intrakranielle Blutung (1)
- Involution (1)
- Iron-oxide (1)
- Irradiation (1)
- Isoformen (1)
- JAK inhibitor (1)
- JNK (1)
- JUN (1)
- KIT (1)
- KRAS (1)
- KRAS biomarker signatures (1)
- Kaposi sarcoma (1)
- Keimzelltumor (1)
- Keimzentrumsreaktion (1)
- Keratine (1)
- Keratinozyt (1)
- Ki-67 (1)
- KiSS1 (1)
- Kidney cancer (1)
- Kiefernekrosen (1)
- Killerzelle (1)
- Kindesalter (1)
- Klarzellsarkom (1)
- Klassifikation (1)
- Klonale Evolution (1)
- Klonalitaetsanalysen (1)
- Klonalität (1)
- Knochenmetastase (1)
- Knochensialoprotein (1)
- Knock-out-Mäuse (1)
- Kolonkarzinom (1)
- Komparative Genomische Hybridisierung (1)
- Komparative genomische Hybridisierung (1)
- Krebstherapie (1)
- Kreuzreaktion (1)
- LESA (1)
- LGA (1)
- LITAF (1)
- LM-1 (1)
- Lagerungsmedium (1)
- Laminin (1)
- Langfristige Prognose (1)
- Larynxkarzinom (1)
- Lateral suboccipital craniectomy (1)
- Lesions (1)
- Leukoplakia (1)
- Leukoplakie (1)
- Lichen planus (1)
- Lichen ruber planus (1)
- Ligand (1)
- Lipom (1)
- Liposarkom (1)
- Lipotoxizität (1)
- Lokalisation (1)
- Low grade Astrocytoma (1)
- Lung-cancer (1)
- Lymph2Cx assay (1)
- Lymphadenitis (1)
- Lymphdrüse (1)
- Lymphocytes (1)
- Lymphomas (1)
- Lymphozyt (1)
- Lymphsystem (1)
- MAGE A3 (1)
- MAGE-A (1)
- MAGE-A-Antigene (1)
- MAGE-A-antigens (1)
- MALT lymphoma (1)
- MALT-Lymphome (1)
- MALT-Typ Lymphome (1)
- MALT-type lymphoma (1)
- MALT1-Gen (1)
- MALT1-gene (1)
- MAPK (1)
- MCL (1)
- MDS (1)
- MEF2D (1)
- MEK/ERK-signaling (1)
- MGMT (1)
- MGMT promoter methylation (1)
- MHC (1)
- MITF-low (1)
- MIZ1 (1)
- MMP2 (1)
- MMP9 (1)
- MRSA (1)
- MTB (1)
- MTCH2 (1)
- MTX (1)
- Malignancies (1)
- Malt (1)
- Mantelzellen (1)
- Mantelzelllymphom (1)
- Marginal zone lymphomas (1)
- Marginalzonen-B-Zell-Lymphom (1)
- Marginalzonen-Lymphome (1)
- Masaoka (1)
- Maschinelles Lernen (1)
- Mediastinum (1)
- Medical research (1)
- Mensch (1)
- Merlin (1)
- Metastases (1)
- Mikroglia (1)
- Mikrosatelliten (1)
- Mikrosatelliten-Instabilität (1)
- Milz (1)
- Mismatch (1)
- Molecular pathogenesis (1)
- Molekulargenetik (1)
- Monoklonaler Antikrper (1)
- Morphometrie (1)
- Mukosa-assoziiertes lymphatisches Gewebe (1)
- Multigentests (1)
- Multiple Sklerose (1)
- Mundhöhlentumor (1)
- Muskelzelle (1)
- Mutation (1)
- MyD88 (1)
- Myasthenia gravi (1)
- Myb-MuvB (1)
- Myc (1)
- Myeloma cells (1)
- Myelomas (1)
- Mykose (1)
- Mysthenia Gravis (1)
- N-Glykosylierungsmotive (1)
- N-glycosylation sites (1)
- NEC (1)
- NET (1)
- NF-KAPPA-B (1)
- NF-\(\kappa\)B pathway (1)
- NF-κB (1)
- NF2-related schwannomatosis (NF2) (1)
- NFAT in EAE (1)
- NFATc (1)
- NFATc1 sumoylation (1)
- NFATc1/αA (1)
- NFATc3 (1)
- NFATs (1)
- NFE2L2 (1)
- NFkappaB (1)
- NGS (1)
- NHLRC2 (1)
- NIH-3T3 (1)
- NLPHL (1)
- NORM-1 (1)
- NR3C1 (1)
- NSG (1)
- NSG-SGM3 (1)
- NY-ESO 1 (1)
- Natürliche Killerzelle (1)
- Nebennierenrinde (1)
- Nebennierenrindenkrebs (1)
- Nestin (1)
- Neurodegeneration (1)
- Nicotinischer Acetylcholinrezeptor (1)
- Nierenzellcarcinom (1)
- Nodo-parandopathy (1)
- Non Hodgkin Lymphoma (1)
- Non Hodgkin Lymphome (1)
- Non-Hodgkin Lymphome (1)
- Non-Hodgkin-Lymphome (1)
- Nrf2 (1)
- Nuclear Factor of Activated T cells (NFAT) (1)
- Nuclear expression (1)
- Nur77 (1)
- OBF-1 OCA-B (1)
- OCT-1-deficient mice (1)
- Oncotype DX® (1)
- OncotypeDX (1)
- OncotypeDX\(^{®}\) (1)
- Oral Precancer (1)
- Oral mucosa (1)
- Oral squamous cell carcinoma (1)
- Organoids (1)
- Osteoarthrose (1)
- Osteogeneration (1)
- Osteopontin (1)
- PAI-1 (1)
- PAM-1 (1)
- PAT-LM1 (1)
- PAT-SM6 (1)
- PCDHGC3 (1)
- PCI-32765 (1)
- PD-1 (1)
- PI3K (1)
- PKA (1)
- PLAG1 rearrangement (1)
- POLKADOTS (1)
- PRDI-BF1 (1)
- PRRT (1)
- PTCL NOS (1)
- PTEN (1)
- Paraffin (1)
- Parkinson (1)
- Parkinsons disease (1)
- Parkinson’s disease (1)
- Particles (1)
- Pathohistologie (1)
- Pathway (1)
- Pentixafor (1)
- Phylogenetik (1)
- Phänotyp (1)
- Plaques und Tangels (1)
- Plattenepithelkarzinom (1)
- Polyadenylierung (1)
- Polymerase-Kettenreaktion (1)
- Positron emission tomography (1)
- Positronen-Emissions-Tomografie (1)
- Posttranskriptionelle Regulation (1)
- Pou2af1 (1)
- Primär kutane Marginalzonen-Lymphome (1)
- Primär kutanes Lymphom (1)
- Profiling (1)
- Prog (1)
- Prognosis (1)
- Proliferation index (1)
- Proliferationsindex (1)
- Promoter (1)
- Promotor (1)
- Promotor <Genetik> (1)
- Prophylaxe (1)
- Prostata-DNA-Datenbank (1)
- Prostatakarzinom (1)
- Protein-DNA-Interaktion (1)
- Protein-Protein-Interaktion (1)
- Präkanzerose (1)
- Präkanzerosen (1)
- R-CHOP (1)
- RCC (1)
- RNA Expression (1)
- RNA probe (1)
- RNA-Sequenzierung (1)
- RNAPOL1 (1)
- RNAScope (1)
- ROS (1)
- RPS27 (1)
- RYGB (1)
- Rac (1)
- Raf (1)
- Random Forest (1)
- Rats (1)
- Receptor-Tyrosine Kinases (1)
- Regulatorgen (1)
- Regulatory-cells (1)
- Reifung (1)
- Renal cell carcinoma (1)
- Restriktionsfragmentlängenpolymorphismus (1)
- Retroperitoneum (1)
- Retroviraler Gentransfer (1)
- Rezeptor (1)
- Rezeptor-Expression (1)
- Rezeptor-Tyrosinkinasen (1)
- Rhabdomyosarkom (1)
- Rheumatoid arthritis (1)
- Rheumatoide Arthritis (1)
- Rho-GTPases (1)
- Ribosomale RNS (1)
- Richter's syndrome (1)
- Richter-Syndrom (1)
- Risiko (1)
- Risikofaktoren (1)
- Risk factors (1)
- Rituximab plus (1)
- Riutximab (1)
- Rotatorenmanschettensyndrom (1)
- S-Phase-Fraktion (1)
- S-phase fraction (1)
- SAM-6 (1)
- SARS-CoV-2 (1)
- SB332235 (1)
- SGN-35 (1)
- SHARP-Screening (1)
- SIV (1)
- SLC7A11 (1)
- SOAT1 (1)
- SSTR (1)
- STEAP-1 (1)
- Sarkom (1)
- Schleimhaut (1)
- Schleimhaut-Ulzera (1)
- Schütteltrauma (1)
- Senile Lymphoproliferation (1)
- Sequenzdaten (1)
- Skelettmuskulatur (1)
- Soft-tissue infection (1)
- Sox9 (1)
- Speicheldrüsenkrebs (1)
- Speiseröhre (1)
- SphK1 (1)
- Spinal dissemination (1)
- Spindle cell (1)
- Spleen (1)
- Sporadic Alzheimer’s disease (1)
- Sporadische Alzheimer-Demenz (1)
- Sprue (1)
- Squamous cell carcinoma (1)
- Staging (1)
- Stammzelltransplantation (1)
- Stanzbiopsie (1)
- Staphylococcus aureus (1)
- Staphylococcus aureus immune response (1)
- Starry Sky (1)
- Sternberg-Riesenzelle (1)
- Sunitinib (1)
- Suppression (1)
- Surgery (1)
- Survival (1)
- Synovialmembran (1)
- Synovialsarkom (1)
- T Lymphocytes (1)
- T Zellen (1)
- T cell differentiation (1)
- T cell receptors (1)
- T helper cells (1)
- T lymphocyte (1)
- T(H)17 cells (1)
- T-Helfer Zellen (1)
- T-Lymphozyt info (1)
- T-Zell-Entwicklung (1)
- T-Zell-Lymphom (1)
- T-Zell-Marker (1)
- T-Zell-Reifung (1)
- T-Zell-Rezeptor (1)
- T-Zelldifferenzierung (1)
- T-cell non-Hodgkin's lymphomas (1)
- T-cell receptor (1)
- T-cell transfer (1)
- T-cells (1)
- T-follicular regulatory cell (1)
- T-lymphocytes (1)
- TAD-A (1)
- TCR signaling cascade (1)
- TGF-alpha (1)
- TP53 (1)
- TP53 mutations (1)
- T\(_{reg}\) and Foxp3 (1)
- Targeted Therapies (1)
- Targets (1)
- Telepathologie (1)
- Temozolomide (1)
- Th (1)
- Th17 (1)
- Therapie (1)
- Thomas (Arzt) (1)
- Thymocytes (1)
- Thymoma (1)
- Thymome (1)
- Thymopoese (1)
- Thymuskrankheit (1)
- Tissue-Microarray-Technik (1)
- Tlymphozyten (1)
- Tolerance (1)
- Toleranz <Biologie> (1)
- Tonsilla (1)
- Tracking (1)
- Transcription factors (1)
- Transcription-factor (1)
- Transkription <Genetik> (1)
- Transkriptionfaktoren (1)
- Transkriptionsfaktor NF-KappaB (1)
- Transkriptionsfaktor info (1)
- Translational research (1)
- Translokation (1)
- Translokation t(11;14)(q13;q32) (1)
- Translokation t(11;18) (1)
- Transplantat-Wirt-Reaktion (1)
- Transplantatabstoßung (1)
- Tregs (1)
- Trisomie (1)
- Tumor Microenvironment (1)
- Tumor Treating Fields (TTFields) (1)
- Tumor-necrosis-factor (1)
- Tumorantigen (1)
- Tumorimmunity (1)
- Tumorimmunität (1)
- Tumornephrektomie (1)
- Tumorprogression (1)
- Tumorzell-Migration (1)
- Tumour markers (1)
- Typ 1 Muskelfasern (1)
- Tyrosine kinase inhibition (1)
- UMAP (1)
- USP8 (1)
- USP9X (1)
- UV-Strahlung (1)
- Urothelkarzinom (1)
- Usage (1)
- Uveitis (1)
- VDR (1)
- VH-JgG Mutationen (1)
- Vascular endothelial Growth Factor (1)
- Venenlagerung (1)
- Verlust der Heterozygosität (1)
- Vielfalt (1)
- Virtual Microscopy (1)
- Virtuelle Mikroskopie (1)
- Vitamin-K-Mangel-Blutung (1)
- Vorhersage (1)
- WHO (1)
- WHO-Klassifikation (1)
- WNT signaling (1)
- WTAP (1)
- Waldeyer-Ring (1)
- Waldeyer´s ring (1)
- Waldeyer’s tonsillar ring (1)
- Wilms tumour (1)
- XIAP (1)
- YAP (1)
- Zellmigration (1)
- Zelltod (1)
- Zellzyklus (1)
- Zentroblastisches Lymphom (1)
- Zytokeratin (1)
- [18F]FDG-PET-CT (1)
- [18F]Fluorodeoxythymidine (1)
- [\(^{68}\)Ga] pentixafor (1)
- [\(^{68}\)Ga]Pentixafor (1)
- \(^{68}\)Ga-Pentixafor (1)
- abdominal lymph node metastases (1)
- aberrations (1)
- abnormalities (1)
- actin (1)
- actin filament (1)
- actin filaments (1)
- activated B cell-like diffuse large B-cell lymphoma (ABC-DLBCL) (1)
- activation (1)
- acute esophageal necrosis (1)
- acute graft-versus host disease (1)
- acute graft-versus-host disease (1)
- acute lymphoblastic leukemia (1)
- acute lymphocytic leukaemia (1)
- acute myeloid leukaemia (1)
- acute myeloid leukemia (1)
- adenomas (1)
- adenosine kinase (1)
- adhesion (1)
- adrenal glands (1)
- adrenal tumor (1)
- adrenocortical (1)
- adrenocortical cancer (1)
- adrenocortical tissues (1)
- adrenocortical tumors (1)
- affinity (1)
- aggressive B‐cell lymphoma (1)
- allergy (1)
- allogenic stem cell transplantation (1)
- allografts (1)
- alternative splicing (1)
- aluminum granuloma (1)
- aminoacyl‐tRNA synthetases (1)
- amplifications (1)
- amyloidoma (1)
- amyloidosis (1)
- anaplasia (1)
- anaplastic large T-cell-lymphoma (1)
- anaplastic large cell lymphoma (1)
- anaplastic large cell lymphoma (ALCL) (1)
- anaplastic medulloblastoma (1)
- anaplastisch-großzellige T-Zell-Lymphome (1)
- aneuploidy (1)
- aneusomy (1)
- angeborenes Immunsystem (1)
- annecin-V (1)
- anti-CD30 drug conjugate (1)
- anti-inflammatory cytokines (1)
- antibodies (1)
- antibody (1)
- antibody-mediated (1)
- antigen loss (1)
- antigens (1)
- antikörpervermittelt (1)
- antioxidant function (1)
- aortic adventitia (1)
- aortokoronarer Venenbypass (1)
- apoptosis, Myc (1)
- appendicitis (1)
- arteriovenous loop (1)
- atopic dermatitis (1)
- atrial natriuretic peptide (1)
- aurora kinase A polymorphism (1)
- aurorakinase B (1)
- autoantibodies (1)
- autoantibody (1)
- autoantigen (1)
- autoimmune regulator (1)
- autoimmunregulator (1)
- autoimmuns gastitis (1)
- autologous transplantation (1)
- autophagy (1)
- axonally transported proteins (1)
- azacitidine (1)
- b-cell lymphoma of the MALT type (1)
- b-cell lymphomas (1)
- b-cell receptor (1)
- bacterial toxins (1)
- behavior (1)
- benige tumor (1)
- beta-catenin (1)
- binding (1)
- binding proteins (1)
- biofluid (1)
- bioinformatic clustering (1)
- biological sciences (1)
- biomarker prediction (1)
- biopsy (1)
- biosynthesis (1)
- bisphosphonate (1)
- blood–brain barrier (1)
- bone disease (1)
- bone marrow biopsy (1)
- bone marrow cells (1)
- bone marrow–spleen–liver large B‐cell lymphoma (1)
- bone metastases (1)
- bone metastasis (1)
- bone sialoprotein (1)
- boolean in silico models (1)
- botulinum C2 toxin (1)
- breast carcinoma (1)
- buparlisib (1)
- c-MYC (1)
- c-kit (1)
- c-myc (1)
- c/ebp (1)
- cAMP (1)
- cadaver multiorgan preservation (1)
- calcium (1)
- cancer care (1)
- cancer detection (1)
- cancer diagnosis (1)
- cancer metabolism (1)
- cancer of unknown primary (CUP) (1)
- cancer treatment (1)
- carcinogenesis (1)
- carcinoma (1)
- carcinoma metastases to pancreas (1)
- cardiac transplantation (1)
- cardiomyocyte proliferation (1)
- cartilage oligomeric matrix protein (1)
- caspase-3 (1)
- catenin (1)
- caveolin-1 (1)
- cell binding (1)
- cell cycle and cell division (1)
- cell death (1)
- cell of origin (1)
- cells (1)
- cellular uptake (1)
- centroblastic lymphoma of the multilobated subtype (1)
- cerebellum (1)
- cerebral cortex (1)
- cerebropulmonary disease (1)
- cetuximab (1)
- checkpoint inhibition (1)
- chemokine receptor-4 (1)
- chemokinereceptor (1)
- childhood (1)
- childhood interstitial lung disease (1)
- children (1)
- children´s interstitial lung disease (chILD) lipoid pneumonia (1)
- cholesterol pneumonia (1)
- cholesterol pneumonitis (1)
- chromatin (1)
- chromosome 18 (1)
- chromosome 9 (1)
- chromosomes (1)
- chronic IBD model (1)
- chronic lymphocytic leukemia (1)
- chronische B-Zell Leukaemie (1)
- chronophin (1)
- classical Hodgkin lymphoma (1)
- cleavage (1)
- clonal evolution (1)
- clonality (1)
- clostridium botulinum (1)
- coactivator OBF-1 (1)
- coated vesicles (1)
- cofilin (1)
- colorectal carcinoma (1)
- combined immunodeficiency (1)
- combined therapy (1)
- complement system (1)
- complex (1)
- confocal Raman imaging (1)
- consensus DNA (1)
- cross-priming (1)
- cross-reaction (1)
- cutaneous T-cell-lymphoma (1)
- cycle (1)
- cyclophsophamide (1)
- cyclosporin A (1)
- cyclosporine A (1)
- cytokeratin (1)
- cytotoxicity (1)
- damage (1)
- damage responses (1)
- deafness (1)
- deformation (1)
- deletions (1)
- diagnosis (1)
- diagnostics (1)
- differentiation (1)
- diffuse large B-Cell lymphoma (1)
- diffuse large B‐cell lymphoma (1)
- disease (1)
- distinct (1)
- down regulation (1)
- drug abuse (1)
- drug resistance (1)
- drug therapy (1)
- eGFP (1)
- early (1)
- early breast cancer (1)
- early diagnosis (1)
- echocardiography (1)
- ectopic lymphoid follicle (1)
- effector Treg (eTreg) (1)
- egfr (1)
- ejection fraction (1)
- embryonic lethality (1)
- encephalitis (1)
- encephalitis lethargica (1)
- endothelium (1)
- enhancer (1)
- enteropathy-type (1)
- ependyoma (1)
- ephitelial cells (1)
- epigenetics (1)
- epithelial markers (1)
- epithelium (1)
- extracorporeal membrane oxygenation (1)
- extrafollicular activation (1)
- extramedullary disease (1)
- features (1)
- ferroptosis (1)
- fetaler Acetylcholinrezeptor (1)
- fibroblast activation protein (1)
- fixation (1)
- fluorenscence (1)
- fluorescence in situ hybridisation (1)
- fluorescent-in -situ-hybridization (1)
- foetal typ acetylcholine receptor (1)
- follicular T helper cells (1)
- follicular lymphoma reactive germinal centers (1)
- follicular regulatory T cell (1)
- follikuläre Lymphome erhaltene reaktive Keimzentren (1)
- follikuläre regulatorische T-Zelle (1)
- follikulärer (1)
- forecasting (1)
- formalin (1)
- formalin-fixed (1)
- formalin-fixiert (1)
- functional characterization (1)
- fungal infection (1)
- gRNA-only (1)
- gastric bypass (1)
- gastrointestinal infections (1)
- gefitinib (1)
- genetic loci (1)
- genomic aberrations (1)
- germinal center formation (1)
- germline mutation (1)
- gesolin function (1)
- glioblastoma multiforme (GBM) (1)
- glucocorticoid excess (1)
- glutaminase inhibition (1)
- goldfish optic nerve (1)
- group 3 (1)
- growth (1)
- growth pattern (1)
- growth patterns (1)
- growth-associated protein (1)
- großzellige (1)
- gut–liver axis (1)
- haematological cancer (1)
- head and neck (1)
- head and neck cancer (1)
- heart (1)
- heart failure (1)
- heatshockprotein (1)
- helicobacter (1)
- helicobacter pylori (1)
- helper T cells (1)
- helper T-cells (1)
- hematopoiesis (1)
- hematopoietic stem cells (1)
- hemophagocytosis (1)
- hepcidin (1)
- high numbers (1)
- high-dose chemotherapy (1)
- high-resolution analysis (1)
- high-risk Prostate Cancer (1)
- high‐grade B‐cell lymphoma (1)
- hippocampal stem cells (1)
- histopathology (1)
- hnRNP K (1)
- hormones (1)
- human (1)
- human antibodies (1)
- human brain (1)
- human cerebral endothelial cells (1)
- human genome (1)
- human monoclonal antibodies (1)
- human monoclonal antibody LM-1 (1)
- human monoclonal antibody PAM-1 (1)
- humane Antikörper (1)
- humane monoklonale Antikörper (1)
- humaner monoklonaler Antikörper LM-1 (1)
- humaner monoklonaler Antikörper PAM-1 (1)
- humanized hemato-lymphoid mice (1)
- humanized mice (1)
- hybridization (1)
- hyper-IgM syndrome type 2 (HIGM2) (1)
- hypercortisolism (1)
- hypermutation (1)
- iiron transporter (1)
- immune cells (1)
- immune check inhibitor (1)
- immune checkpoint blockade (1)
- immune checkpoint inhibitor (ICI) (1)
- immune evasion (1)
- immune infiltration (1)
- immune system (1)
- immunhistochemical analysis of DLBCL (1)
- immunhistochemisch (1)
- immunhistochemische Analyse von DLBCL (1)
- immunity (1)
- immunocytochemistry (1)
- immunofuorescence double staining (1)
- immunoglobulin promoters (1)
- immunoglobuline (1)
- immunohistochemisty (1)
- immunohistological expression analysis (1)
- immunology and microbiology section (1)
- immunophenotype (1)
- immunotherapeutics (1)
- in silico analysis (1)
- in-situ-Hybridisierung (1)
- in-situ-hybridization (1)
- in-vitro (1)
- in-vivo (1)
- independent predictor (1)
- induction (1)
- induction of apoptosis (1)
- inflammation-induced tissue demage (1)
- innate Immunität (1)
- innate antibody (1)
- integrated stress response (1)
- integrin (1)
- interaction (1)
- interleukin-8 (1)
- interleukins (1)
- intestine (1)
- intracranial bleeding (1)
- intraosseous (1)
- intravascular large B‐cell lymphoma (1)
- invasion (1)
- involution (1)
- involvement (1)
- iron in parkinsonism (1)
- iron model (1)
- iron pathology (1)
- isoforms (1)
- karyotype (1)
- kidney cancer (1)
- kinase (1)
- kinases (1)
- kinetic mechanism (1)
- knock down (1)
- knock out mice (1)
- kolorektales Karzinom (1)
- komparative genomische Hybridisierung (1)
- kras (1)
- kras-Mutation (1)
- large cell transformation (1)
- latency type (1)
- lck (1)
- lesions (1)
- leukemia (1)
- lichen planus (1)
- lineage (1)
- lineage differentiation (1)
- lipid droplets (1)
- lipids (1)
- lipoblastoma (1)
- lipoid pneumonitis (1)
- lipotoxicity (1)
- liquid biopsy (1)
- liraglutide (1)
- livin (1)
- lung fibrosis (1)
- lymph node (1)
- lymph node stromal cells (1)
- lymph node transplantation (1)
- lymphatische Tumoren (1)
- lymphocyte (1)
- lymphocyte activation (1)
- lymphocyte differentiation (1)
- lymphohistiocytosis (1)
- lymphoid aggregate (1)
- lymphoid hyperplasia (1)
- lymphoid tissues (1)
- lymphoid-tissue (1)
- lymphoid-tissue lymphomas (1)
- lymphomas (1)
- mTOR (1)
- major histocompatibility complex (1)
- malignancies (1)
- malt lymphoma (1)
- mammalian cells (1)
- mandible (1)
- mantel cell lymphoma (1)
- marcophages (1)
- marginal zone-B-cell-Lymphoma (1)
- marrow transplantation (1)
- mass cytometry (1)
- mast cells (1)
- mastocytosis (1)
- measles virus (1)
- mediastinum (1)
- medical research (1)
- medicine (1)
- membrane topology (1)
- membrane translocation (1)
- memory B cells (1)
- meningeal inflammation (1)
- meningioma (1)
- mesenchymal markers (1)
- mesenteric lymph node (1)
- mesentery (1)
- messenger-RNA transport (1)
- metabolism (1)
- metagenomics (1)
- metastasis associated in colorectal cancer 1 (MACC1) (1)
- metastasis-associated in colon cancer 1 (MACC1) (1)
- methylation (1)
- miR-126 (1)
- miR-21 (1)
- microRNA-221 (1)
- microglia (1)
- microsatellite analysis (1)
- microsatellites (1)
- microvessel permeability (1)
- mikrobielle Diversität (1)
- mild hypothermia (1)
- mitochondriale DNA (1)
- mitochondriale DNA-Deletionen (1)
- mitosis (1)
- mitotane (1)
- mitotic genes (1)
- molecular marker (1)
- molecular subtypes (1)
- monoklonale Antikörper (1)
- monoklonaler Antikörper (1)
- morphometry (1)
- mouse model (1)
- mtDNA (1)
- mucosa-associated lymphatic tissue (1)
- mucosal ulcers (1)
- multifocal growth (1)
- multigene-array (1)
- multilobulierte centroblastische Lymphome (1)
- multiple Sclerosis immunomodulation Natalizumab (1)
- multiple sclerosis (1)
- multivariate Prognoseanalyse (1)
- multivariate data analysis (1)
- multi‐organ disease (1)
- murine homolog (1)
- mutant p53 (1)
- mutational targeting (1)
- myasthenia (1)
- mycosis fungoides (1)
- myeloma (1)
- naive T-cell gene editing (1)
- natural IgG antibody (1)
- natural IgM antibodies (1)
- natural antibodies (1)
- natürliche IgM-Antikörper (1)
- natürlicher IgG-Antikörper (1)
- negative selection (1)
- nephroblastoma (1)
- nervous system (1)
- network (1)
- neurodegeneration (1)
- neurodegenerative disease (1)
- neuroendocrine tumor (1)
- neurogene Schädigung (1)
- neuromelanin (1)
- neuromucular disorders (1)
- neurooncology (1)
- neuropathology (1)
- neuroscience (1)
- neurotoxicity (1)
- neurovascular unit (1)
- neutral loss (1)
- next generation sequencing (1)
- niche (1)
- nicotinic acetylcholine receptor (1)
- nodal (1)
- nodal peripheral T-cell lymphoma (1)
- nodales peripheres T-Zell-Lymphom (1)
- nodular lymphcyte (1)
- non-GCB-Subtyp (1)
- non-GCB-like (1)
- non-Hodgkin lymphoma (1)
- non-hodgkin lymphoma (1)
- non-hodgkin-lymphoma (1)
- non-small cell lung cancer (1)
- noncoding RNAs (1)
- normal adrenal glands (1)
- notch signaling (1)
- nuclear DNA content (1)
- nuclear localization (1)
- nukleare DNA-Inhalt (1)
- nur77 (1)
- obinutuzumab (1)
- octreotide (1)
- olfactory bulb (1)
- oncogene (1)
- oncogenesis (1)
- oncology (1)
- organotypic hippocampal slice cultures (OHSC) (1)
- orthotopic xenograft (1)
- osteoarthritis (1)
- osteonecrosis of jaw (1)
- outcomes research (1)
- outreach (1)
- oxidativer Stress (1)
- p300 (1)
- p53 expression (1)
- p53-dependent apoptosis (1)
- p53-inducible regulator (1)
- pFADD (1)
- paediatric cancer (1)
- pan-RCC (1)
- panel sequencing (1)
- panel-sequencing (1)
- panniculitis (1)
- paraffin-eingebettet (1)
- paraffin-embedded (1)
- parathyroid carcinoma (1)
- parkinson’s disease (1)
- pathohistology (1)
- pathology (1)
- pathway (1)
- patient access (1)
- patient survival (1)
- pediatric (1)
- pediatric lymphoma (1)
- pembrolizumab (1)
- peptide receptor radionuclide therapy (1)
- peptide receptor radionuclide therapy (PRRT) (1)
- peptide tyrosine tyrosine (PYY) (1)
- peptide tyrosine tyrosine 3-36 (PYY\(_{3-36}\)) (1)
- peripheral T-cell (1)
- peripheral T-cell lymphoma (1)
- periphere T-Zell-Lymphome (1)
- phosphatase 2A (1)
- phospholipase A(2) (1)
- plasmablasts (1)
- pleural mesothelioma (1)
- polyadenylation (1)
- post-mortem heart recovery (1)
- postencephalitic parkinsonism (1)
- posttranslational modification (1)
- posttranslationale Modifikation (1)
- potentiell therapeutisch relevante Proteine (1)
- pre-B (1)
- precancerous lesions (1)
- precision oncology (1)
- prediction (1)
- predictive markers (1)
- primary bone marrow presentation (1)
- primary cell culture (1)
- primary cutaneous follicular B-cell lymphoma (1)
- primary cutaneous lymphoma (1)
- primary cutaneous marginal zone lymphomas (1)
- pro-B (1)
- pro-inflammatory cytokines (1)
- prognostic factor (1)
- prognostic factors (1)
- prognostic marker (1)
- prognostic value (1)
- progressive multiple sclerosis (1)
- proliferation (1)
- prophylaxis (1)
- prostate cancer (1)
- prostate carcinoma (1)
- prostate gland DNA – database (1)
- prostate gland cancer (1)
- protein and mRNA expression (1)
- proteins (1)
- pseudocarcinomatous hyperplasia (1)
- pseudolymphoma (1)
- psoas muscle (1)
- psoriasis (1)
- radiation (1)
- radiation-induced migration (1)
- rag (1)
- raman spectroscopy (1)
- rare SNP (1)
- real world data (1)
- receptor expression (1)
- recurrence-free survival (1)
- refractory/relapsed lymphoma (1)
- regional development (1)
- regulatory T-cells (1)
- renal cancer (1)
- renal cell carcinoma (1)
- repeated surgery (1)
- resistance (1)
- resistance to apoptosis (1)
- restoration (1)
- retroperitoneal tumor (1)
- retroperitoneum (1)
- retroviral gene transfer (1)
- retroviral vector system (1)
- retrovirales Vektorsystem (1)
- reverse transcriptase-polymerase chain reaction (1)
- rhesus monkeys (1)
- rheumatoid arthritis (1)
- rheumatoiden Arthritis (1)
- ribosome (1)
- ribosyltransferase (1)
- risk (1)
- roquin (1)
- rotator-cuff injury (1)
- sFas (1)
- salivary gland (1)
- salivary gland neoplasia (1)
- salivary gland tumor (1)
- salivary gland tumors (1)
- salivary glands (1)
- sarcoma (1)
- scoring system (1)
- selective vulnerability (1)
- selektive Vulnerabilität (1)
- seminoma (1)
- senescence (1)
- senile Lymphoproliferation (1)
- serum (1)
- shaken baby syndrome (1)
- siv (1)
- slice culture (1)
- somatic hypermutation (1)
- somatic mutations (1)
- somatostatine (1)
- spinal-cord-injury (1)
- spleen (1)
- splice variant (1)
- sporadische Alzheimer-Demenz (1)
- squamous tumors (1)
- staphylococcal abscess (1)
- stem cell transplantation (1)
- stem-cells (1)
- stemness (1)
- stomach carcinoma (1)
- storage solution (1)
- stratification (1)
- subventricular zone (1)
- suppression (1)
- suppressor (1)
- surgery (1)
- surgical and invasive medical procedures (1)
- surgical treatment (1)
- systemic sclerosis (1)
- t cells (1)
- t(11;18)(q21;q21) (1)
- t(14;18)-negative follicular lymphoma (1)
- t(14;18)-negative follikuläre Lymphome (1)
- t-SNE (1)
- t-cell maturation (1)
- t-cell-lymphoma (1)
- target (1)
- target validation (1)
- targeted (1)
- targeted combination therapy (1)
- targeted sequencing (1)
- targeted therapies (1)
- tauopathy (1)
- telepathology (1)
- tetraspanin (1)
- tetraspanin protein (1)
- theranostics (1)
- therapeutic target (1)
- therapy response (1)
- thiol starvation (1)
- thymic epithelial tumor (1)
- thymitis (1)
- thymocytes (1)
- thymopoiesis (1)
- tissue preparation (1)
- tissuemicroarray (1)
- tofacitinib (1)
- transcript (1)
- transcription factor FOXP1 (1)
- transcriptional repression (1)
- transcriptome (1)
- transcriptomic analysis (1)
- transformation (1)
- translational research (1)
- translocation t(11;14)(q13;q32) (1)
- translocation t(11;18) (1)
- transplantation (1)
- trastuzumab (1)
- trastuzumab deruxtecan (1)
- treatment regimens (1)
- treg cells (1)
- triple-negative breast cancer (1)
- trisomy (1)
- tumor (1)
- tumor cell migration (1)
- tumor heterogeneity (1)
- tumor progression (1)
- tumor slice cultures (1)
- tumor specific antibody (1)
- tumor spheroids (1)
- tumor vaccination (1)
- tumor-vessel wall-interface model (1)
- tumorigenesis (1)
- tumormicroenvironment (1)
- tumors (1)
- tumorspecific (1)
- tumorspezifisch (1)
- tumorspezifische Antikörper (1)
- tumour heterogeneity (1)
- tumour-necrosis factors (1)
- typ 1 muscle fibres (1)
- tyrosine kinase inhibitor (TKI) (1)
- uPA (1)
- ubiquitin (1)
- unspezifische Lymphadenitis (1)
- unsupervised clustering (1)
- up regulation (1)
- urinary bladder cancer (1)
- urothelial carcinoma (1)
- vascular wall stem and progenitor cells (1)
- vascularization model (1)
- vasculogenesis (1)
- vemurafenib (1)
- venetoclax (1)
- virus–iron interaction (1)
- visual clustering (1)
- vitamin D receptor (1)
- vitamin k deficiency bleeding (1)
- vitamin metabolism (1)
- von Economo (1)
- whole-exome sequencing (1)
- xxx (1)
- Östrogene (1)
- Überleben (1)
- Überlebenszeit (1)
- ɑ-Synuclein and iron (1)
- α-synuclein-specific T cells (1)
Institute
- Pathologisches Institut (334)
- Medizinische Klinik und Poliklinik II (30)
- Theodor-Boveri-Institut für Biowissenschaften (30)
- Comprehensive Cancer Center Mainfranken (27)
- Neurochirurgische Klinik und Poliklinik (21)
- Medizinische Klinik und Poliklinik I (20)
- Klinik und Poliklinik für Nuklearmedizin (19)
- Klinik und Poliklinik für Allgemein-, Viszeral-, Gefäß- und Kinderchirurgie (Chirurgische Klinik I) (13)
- Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie (12)
- Graduate School of Life Sciences (10)
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (9)
- Kinderklinik und Poliklinik (9)
- Institut für Virologie und Immunbiologie (8)
- Urologische Klinik und Poliklinik (8)
- Institut für Rechtsmedizin (7)
- Neurologische Klinik und Poliklinik (7)
- Rudolf-Virchow-Zentrum (7)
- Klinik und Poliklinik für Hals-, Nasen- und Ohrenkrankheiten, plastische und ästhetische Operationen (5)
- Klinik und Poliklinik für Mund-, Kiefer- und Plastische Gesichtschirurgie (5)
- Lehrstuhl für Tissue Engineering und Regenerative Medizin (5)
- Center for Computational and Theoretical Biology (4)
- Institut für Anatomie und Zellbiologie (4)
- Institut für Molekulare Infektionsbiologie (4)
- Klinik und Poliklinik für Strahlentherapie (4)
- Lehrstuhl für Orthopädie (4)
- Institut für Pharmakologie und Toxikologie (3)
- Institut für diagnostische und interventionelle Neuroradiologie (ehem. Abteilung für Neuroradiologie) (3)
- Klinik und Poliklinik für Anästhesiologie (ab 2004) (3)
- Klinik und Poliklinik für Thorax-, Herz- u. Thorakale Gefäßchirurgie (3)
- Abteilung für Funktionswerkstoffe der Medizin und der Zahnheilkunde (2)
- Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II) (2)
- Deutsches Zentrum für Herzinsuffizienz (DZHI) (2)
- Frauenklinik und Poliklinik (2)
- Institut für Humangenetik (2)
- Julius-von-Sachs-Institut für Biowissenschaften (2)
- Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie (2)
- Klinik und Poliklinik für Unfall-, Hand-, Plastische und Wiederherstellungschirurgie (Chirurgische Klinik II) (2)
- Augenklinik und Poliklinik (1)
- Institut für Klinische Neurobiologie (1)
- Institut für Pharmazie und Lebensmittelchemie (1)
- Klinik und Poliklinik für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie (1)
- Klinik und Polikliniken für Zahn-, Mund- und Kieferkrankheiten (1)
- Lehrstuhl für Biochemie (1)
- Physikalisches Institut (1)
Sonstige beteiligte Institutionen
- Center for Interdisciplinary Clinical Research, Würzburg University, Würzburg, Germany (1)
- Department of Paediatric Radiology, Institute of Diagnostic and Interventional Radiology, Josef-Schneider-Straße 2, Wuerzburg 97080, Germany (1)
- IZKF Nachwuchsgruppe Geweberegeneration für muskuloskelettale Erkrankungen (1)
- Lehrstuhl für Regeneration Muskuloskelettaler Gewebe (1)
- Muskuloskelettales Centrum Würzburg (MCW) (1)
Background
Medulloblastoma is associated with rare hereditary cancer predisposition syndromes; however, consensus medulloblastoma predisposition genes have not been defined and screening guidelines for genetic counselling and testing for paediatric patients are not available. We aimed to assess and define these genes to provide evidence for future screening guidelines.
Methods
In this international, multicentre study, we analysed patients with medulloblastoma from retrospective cohorts (International Cancer Genome Consortium [ICGC] PedBrain, Medulloblastoma Advanced Genomics International Consortium [MAGIC], and the CEFALO series) and from prospective cohorts from four clinical studies (SJMB03, SJMB12, SJYC07, and I-HIT-MED). Whole-genome sequences and exome sequences from blood and tumour samples were analysed for rare damaging germline mutations in cancer predisposition genes. DNA methylation profiling was done to determine consensus molecular subgroups: WNT (MBWNT), SHH (MBSHH), group 3 (MBGroup3), and group 4 (MBGroup4). Medulloblastoma predisposition genes were predicted on the basis of rare variant burden tests against controls without a cancer diagnosis from the Exome Aggregation Consortium (ExAC). Previously defined somatic mutational signatures were used to further classify medulloblastoma genomes into two groups, a clock-like group (signatures 1 and 5) and a homologous recombination repair deficiency-like group (signatures 3 and 8), and chromothripsis was investigated using previously established criteria. Progression-free survival and overall survival were modelled for patients with a genetic predisposition to medulloblastoma.
Findings
We included a total of 1022 patients with medulloblastoma from the retrospective cohorts (n=673) and the four prospective studies (n=349), from whom blood samples (n=1022) and tumour samples (n=800) were analysed for germline mutations in 110 cancer predisposition genes. In our rare variant burden analysis, we compared these against 53 105 sequenced controls from ExAC and identified APC, BRCA2, PALB2, PTCH1, SUFU, and TP53 as consensus medulloblastoma predisposition genes according to our rare variant burden analysis and estimated that germline mutations accounted for 6% of medulloblastoma diagnoses in the retrospective cohort. The prevalence of genetic predispositions differed between molecular subgroups in the retrospective cohort and was highest for patients in the MBSHH subgroup (20% in the retrospective cohort). These estimates were replicated in the prospective clinical cohort (germline mutations accounted for 5% of medulloblastoma diagnoses, with the highest prevalence [14%] in the MBSHH subgroup). Patients with germline APC mutations developed MBWNT and accounted for most (five [71%] of seven) cases of MBWNT that had no somatic CTNNB1 exon 3 mutations. Patients with germline mutations in SUFU and PTCH1 mostly developed infant MBSHH. Germline TP53 mutations presented only in childhood patients in the MBSHH subgroup and explained more than half (eight [57%] of 14) of all chromothripsis events in this subgroup. Germline mutations in PALB2 and BRCA2 were observed across the MBSHH, MBGroup3, and MBGroup4 molecular subgroups and were associated with mutational signatures typical of homologous recombination repair deficiency. In patients with a genetic predisposition to medulloblastoma, 5-year progression-free survival was 52% (95% CI 40–69) and 5-year overall survival was 65% (95% CI 52–81); these survival estimates differed significantly across patients with germline mutations in different medulloblastoma predisposition genes.
Interpretation
Genetic counselling and testing should be used as a standard-of-care procedure in patients with MBWNT and MBSHH because these patients have the highest prevalence of damaging germline mutations in known cancer predisposition genes. We propose criteria for routine genetic screening for patients with medulloblastoma based on clinical and molecular tumour characteristics.
Das Mutationsspektrum einzelner Gene beziehungsweise zusammengefasster Gengruppen innerhalb von Signalwegen bei Patienten mit Multiplem Myelom wurde in den letzten Jahren eingehend untersucht und charakterisiert. Die Herausforderung besteht nun in der Interpretation der erhobenen Daten, insbesondere der Bewertung einzelner durch Sequenzierung identifizierter Biomarker bezüglich deren prognostischer Aussagekraft und konkreter therapeutischer Relevanz. Als übergeordnetes Ziel gilt die Ableitung von klinischen (Therapie-) Ansätzen. Auf dem Weg zu einem individualisierten Therapieansatz ist entscheidend, dass wir unser Wissen über die funktionelle Relevanz einzelner Mutationen wie hier im IGF1R im Hinblick auf deren Einbettung in Signalnetzwerke und auf das Proliferationsverhalten der MM Zellen erweitern. Konkret wurde im Rahmen der vorliegende Doktorarbeit der Einfluss von zwei IGF1R Punktmutationen, nämlich D1146N (Punktmutation des IGF1R der HMCL L-363) und N1129S (Punktmutation des IGF1R eines Patienten der DSMM XI Kohorte) auf die Proliferation und das nachgeschaltete Signalling in IGF1R-Überexpressionsmodellen der MM Zelllinien AMO-1 und U-266 untersucht. Zur stabilen Transfektion der HMCLs mit IGF1RWT und den zwei IGF1R Mutanten wurde ein Protokoll auf Grundlage des Sleeping Beauty (SB) Transposase Systems genutzt. In dieser und anderen assoziierten Arbeit konnte unter zu Hilfenahme von insgesamt vier verschiedenen gentechnisch veränderter HMCLs gezeigt werden, dass funktionelle Mutationen im IGF1R Effekte auf das Downstream Signalling zum Beispiel die Aktivierung von AKT und ERK, jedoch nicht auf die Zellproliferation haben. Im Vergleich der untersuchten HMCLs konnten jedoch keine verallgemeinerbaren Schlüsse gezogen werden, was die Heterogenität der Erkrankung und die Wichtigkeit der Einzelfallbetrachtung unterstreicht.
Das MM ist eine maligne Erkrankung, die von biologischer und klinischer Heterogenität geprägt ist. Sie ist durch die monoklonale Vermehrung von Plasmazellen charakterisiert. In vorangegangenen Studien wurde eine Häufung von Mutationen in RTK nachgewiesen. Diese gingen mit einem negativen Einfluss auf das Überleben von MM Patientinnen und Patienten einher.
Im Rahmen dieser Arbeit wurde der Einfluss des IGF1R an HMZL mittels siRNA-vermitteltem IGF1R-Knockdown untersucht und dessen Effekt auf das Signalnetzwerk mittels Western Blot Analysen ermittelt. Um die Heterogenität des MM besser abzubilden, wurden sechs verschiedenen HMZL ausgewählt.
Der IGF1R-Knockdown war in allen HMZL sowohl anhand der Reduktion der IGF1R-Expression als auch der IGF1R-Aktivierung deutlich nachweisbar. Stellvertretend für den PI3K/AKT Signalweg wurde die AKT-Aktivierung untersucht, welche nach IGF1R-Knockdown in allen Linien abnahm. Im Ras/Raf/MEK/ERK Signalweg fiel eine deutliche Reduktion der ERK1/2- und MEK-Aktivierung in den von PCL stammenden HMZL L-363 und MM.1S, sowie in JJN-3 mit der Hochrisikotranslokation t(14;16) auf. Entsprechend der Beobachtungen für die AKT-Aktivierung, nahm die PYK2-Aktivierung in allen HMZL nach IGF1R-Knockdown ab, was auf ein Zusammenspiel von IGF1R, PYK2 und AKT in allen HMZL hindeutet.
Zukünftige Untersuchungen werden zeigen, ob IGF1R Inhibitoren alleine oder in Kombination mit z.B. AKT, PYK2 oder Proteasomen-Inhibitoren in bestimmten molekularen MM Subgruppen ein effektives therapeutisches Ziel sind.
Soft tissue tumors of infancy encompass an overlapping spectrum of diseases that pose unique diagnostic and clinical challenges. We studied genomes and transcriptomes of cryptogenic congenital mesoblastic nephroma (CMN), and extended our findings to five anatomically or histologically related soft tissue tumors: infantile fibrosarcoma (IFS), nephroblastomatosis, Wilms tumor, malignant rhabdoid tumor, and clear cell sarcoma of the kidney. A key finding is recurrent mutation of EGFR in CMN by internal tandem duplication of the kinase domain, thus delineating CMN from other childhood renal tumors. Furthermore, we identify BRAF intragenic rearrangements in CMN and IFS. Collectively these findings reveal novel diagnostic markers and therapeutic strategies and highlight a prominent role of isolated intragenic rearrangements as drivers of infant tumors.
Cell adhesion in the multiple myeloma (MM) microenvironment has been recognized as a major mechanism of MM cell survival and the development of drug resistance. Here we addressed the hypothesis that the protein junctional adhesion molecule-A (JAM-A) may represent a novel target and a clinical biomarker in MM. We evaluated JAM-A expression in MM cell lines and in 147 MM patient bone marrow aspirates and biopsies at different disease stages. Elevated JAM-A levels in patient-derived plasma cells were correlated with poor prognosis. Moreover, circulating soluble JAM-A (sJAM-A) levels were significantly increased in MM patients as compared with controls. Notably, in vitro JAM-A inhibition impaired MM migration, colony formation, chemotaxis, proliferation and viability. In vivo treatment with an anti-JAM-A monoclonal antibody (αJAM-A moAb) impaired tumor progression in a murine xenograft MM model. These results demonstrate that therapeutic targeting of JAM-A has the potential to prevent MM progression, and lead us to propose JAM-A as a biomarker in MM, and sJAM-A as a serum-based marker for clinical stratification.
Burkitt lymphoma (BL) is the most common B-cell lymphoma in children. Within the International Cancer Genome Consortium (ICGC), we performed whole genome and transcriptome sequencing of 39 sporadic BL. Here, we unravel interaction of structural, mutational, and transcriptional changes, which contribute to MYC oncogene dysregulation together with the pathognomonic IG-MYC translocation. Moreover, by mapping IGH translocation breakpoints, we provide evidence that the precursor of at least a subset of BL is a B-cell poised to express IGHA. We describe the landscape of mutations, structural variants, and mutational processes, and identified a series of driver genes in the pathogenesis of BL, which can be targeted by various mechanisms, including IG-non MYC translocations, germline and somatic mutations, fusion transcripts, and alternative splicing.
Pan-cancer analyses that examine commonalities and differences among various cancer types have emerged as a powerful way to obtain novel insights into cancer biology. Here we present a comprehensive analysis of genetic alterations in a pan-cancer cohort including 961 tumours from children, adolescents, and young adults, comprising 24 distinct molecular types of cancer. Using a standardized workflow, we identified marked differences in terms of mutation frequency and significantly mutated genes in comparison to previously analysed adult cancers. Genetic alterations in 149 putative cancer driver genes separate the tumours into two classes: small mutation and structural/copy-number variant (correlating with germline variants). Structural variants, hyperdiploidy, and chromothripsis are linked to TP53 mutation status and mutational signatures. Our data suggest that 7–8% of the children in this cohort carry an unambiguous predisposing germline variant and that nearly 50% of paediatric neoplasms harbour a potentially druggable event, which is highly relevant for the design of future clinical trials.
B cell development in bone marrow is a precisely regulated complex process. Through successive stages of differentiation, which are regulated by a multitude of signaling pathways and an array of lineage-specific transcription factors, the common lymphoid progenitors ultimately give rise to mature B cells. Similar to early thymocyte development in the thymus, early B cell development in bone marrow is critically dependent on IL-7 signaling. During this IL-7-dependent stage of differentiation, several transcription factors, such as E2A, EBF1, and Pax5, among others, play indispensable roles in B lineage specification and maintenance. Although recent studies have implicated several other transcription factors in B cell development, the role of NFATc1 in early B cell developmental stages is not known. Here, using multiple gene-manipulated mouse models and applying various experimental methods, we show that NFATc1 activity is vital for early B cell differentiation. Lack of NFATc1 activity in pro-B cells suppresses EBF1 expression, impairs immunoglobulin gene rearrangement, and thereby preBCR formation, resulting in defective B cell development. Overall, deficiency in NFATc1 activity arrested the pro-B cell transition to the pre-B cell stage, leading to severe B cell lymphopenia. Our findings suggest that, along with other transcription factors, NFATc1 is a critical component of the signaling mechanism that facilitates early B cell differentiation.
The NEDD8-activating enzyme (NAE) inhibitor MLN4924 inhibits cullin-RING ubiquitin ligase complexes including the SKP1-cullin-F-box E3 ligase βTrCP. MLN4924 therefore inhibits also the βTrCP-dependent activation of the classical and the alternative NFĸB pathway. In this work, we found that a subgroup of multiple myeloma cell lines (e.g., RPMI-8226, MM.1S, KMS-12BM) and about half of the primary myeloma samples tested are sensitized to TNF-induced cell death by MLN4924. This correlated with MLN4924-mediated inhibition of TNF-induced activation of the classical NFκB pathway and reduced the efficacy of TNF-induced TNFR1 signaling complex formation. Interestingly, binding studies revealed a straightforward correlation between cell surface TNFR1 expression in multiple myeloma cell lines and their sensitivity for MLN4924/TNF-induced cell death. The cell surface expression levels of TNFR1 in the investigated MM cell lines largely correlated with TNFR1 mRNA expression. This suggests that the variable levels of cell surface expression of TNFR1 in myeloma cell lines are decisive for TNF/MLN4924 sensitivity. Indeed, introduction of TNFR1 into TNFR1-negative TNF/MLN4924-resistant KMS-11BM cells, was sufficient to sensitize this cell line for TNF/MLN4924-induced cell death. Thus, MLN4924 might be especially effective in myeloma patients with TNFR1+ myeloma cells and a TNFhigh tumor microenvironment.
Vestibular schwannoma (VS) are benign cranial nerve sheath tumors of the vestibulocochlear nerve. Their incidence is mostly sporadic, but they can also be associated with NF2-related schwannomatosis (NF2), a hereditary tumor syndrome. Metastasis associated in colon cancer 1 (MACC1) is known to contribute to angiogenesis, cell growth, invasiveness, cell motility and metastasis of solid malignant cancers. In addition, MACC1 may be associated with nonsyndromic hearing impairment. Therefore, we evaluated whether MACC1 may be involved in the pathogenesis of VS. Sporadic VS, recurrent sporadic VS, NF2-associated VS, recurrent NF2-associated VS and healthy vestibular nerves were analyzed for MACC1 mRNA and protein expression by quantitative polymerase chain reaction and immunohistochemistry. MACC1 expression levels were correlated with the patients’ clinical course and symptoms. MACC1 mRNA expression was significantly higher in sporadic VS compared to NF2-associated VS (p < 0.001). The latter expressed similar MACC1 concentrations as healthy vestibular nerves. Recurrent tumors resembled the MACC1 expression of the primary tumors. MACC1 mRNA expression was significantly correlated with deafness in sporadic VS patients (p = 0.034). Therefore, MACC1 might be a new molecular marker involved in VS pathogenesis.